Article by Pharmacy Times
“Officials with the FDA have approved tenapanor (Ibsrela, Ardelyx), a 50 mg, twice-daily oral medication for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, according to a press release.
Tenapanor, a novel treatment, is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3. Through this mechanism, treatment results in increased bowel movements and decreased abdominal pain for patients, according to Ardelyx. IBS-C, a subtype of IBS, can cause abdominal discomfort and bloating associated with constipation in patients and symptoms can be disruptive to daily life.
“Ibsrela has the potential to provide IBS-C patients and their doctors with a novel mechanism and an innovative approach to managing IBS-C, a highly burdensome and difficult-to-treat condition affecting more than 11 million people in the United States,” Mike Raab, president and chief executive officer of Ardelyx, said in a statement.”